Blood Reviews
Volume 21, Issue 4 , Pages 173-182, July 2007

Farnesyltransferase inihibitors in hematologic malignancies

Department of Hematology, Hotel Dieu, Place Alexis Ricordeau, 44093 NANTES CEDEX 01, France

published online 13 February 2007.

Summary 

Farnesyltransferase inhibitors (FTIs) inhibit certain cellular signal transduction pathways, and are being evaluated for activity in hematologic malignancies. Tipifarnib and lonafarnib are orally available FTIs that are active against a variety of targets and inhibit several pathways involved in the pathogenesis of hematologic malignancies. FTIs have demonstrated activity in a variety of hematologic diseases, including acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and multiple myeloma. This article reviews the clinical experience with tipifarnib and lonafarnib in the treatment of hematologic malignancies.

Keywords: Acute myeloid leukemia, Chronic myeloid leukemia, Farnesyltransferase inhibitor, Multiple myeloma, Myelodysplastic syndrome, Tipifarnib, Lonafarnib

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0268-960X(06)00075-0

doi:10.1016/j.blre.2006.12.001

Blood Reviews
Volume 21, Issue 4 , Pages 173-182, July 2007

Article Tools

* Image Usage & Resolution